Disease Flare after Discontinuation of Crizotinib in Anaplastic Lymphoma Kinase-Positive Lung Cancer

por Kuriyama, Yuka, Kim, Young Hak, Nagai, Hiroki, Ozasa, Hiroaki, Sakamori, Yuichi, Mishima, Michiaki
Publicado 2013

Usefulness of pro-gastrin-releasing peptide as a predictor of the incidence of brain metastasis and effect of prophylactic cranial irradiation in patients with limited-stage small-...

por Ueki, Kazuhito, Matsuo, Yukinori, Kishi, Noriko, Yoneyama, Masahiro, Yoshida, Hironori, Sakamori, Yuichi, Ozasa, Hiroaki, Hirai, Toyohiro, Mizowaki, Takashi
Publicado 2022

Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells

por Ozasa, Hiroaki, Oguri, Tetsuya, Maeno, Ken, Takakuwa, Osamu, Kunii, Eiji, Yagi, Yoshitaka, Uemura, Takehiro, Kasai, Daishi, Miyazaki, Mikinori, Niimi, Akio
Publicado 2014

Successful treatment with carboplatin and nanoparticle albumin-bound paclitaxel in a patient with pulmonary spindle cell carcinoma

por Tsuji, Takahiro, Kim, Young Hak, Ozasa, Hiroaki, Sakamori, Yuichi, Nagai, Hiroki, Ajimizu, Hitomi, Yagi, Yoshitaka, Furukawa, Atsuyuki, Haga, Hironori, Mishima, Michiaki
Publicado 2015

Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab

por Funazo, Tomoko Yamamoto, Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Yasuda, Yuto, Yoshida, Hironori, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Publicado 2019

Response to chemotherapy with carboplatin plus albumin-bound paclitaxel in a patient with lymphoepithelioma-like thymic carcinoma: A case report

por SHIMA, HIROSHI, OZASA, HIROAKI, TSUJI, TAKAHIRO, AJIMIZU, HITOMI, NOMIZO, TAKASHI, YAGI, YOSHITAKA, SAKAMORI, YUICHI, NAGAI, HIROKI, MINAMIGUCHI, SACHIKO, KIM, YOUNG HAK, MISHIMA, MICHIAKI
Publicado 2016

Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients

por Nomizo, Takashi, Ozasa, Hiroaki, Tsuji, Takahiro, Funazo, Tomoko, Yasuda, Yuto, Yoshida, Hironori, Yagi, Yoshitaka, Sakamori, Yuichi, Nagai, Hiroki, Hirai, Toyohiro, Kim, Young Hak
Publicado 2017

Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series

por Hashimoto, Kentaro, Ozasa, Hiroaki, Yoshizawa, Akihiko, Yoshida, Hiroshi, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Ajimizu, Hitomi, Funazo, Tomoko, Yoshida, Hironori, Sakamori, Yuichi, Hirai, Toyohiro
Publicado 2022

Clinical impact of high serum hepatocyte growth factor in advanced non-small cell lung cancer

por Tsuji, Takahiro, Sakamori, Yuichi, Ozasa, Hiroaki, Yagi, Yoshitaka, Ajimizu, Hitomi, Yasuda, Yuto, Funazo, Tomoko, Nomizo, Takashi, Yoshida, Hironori, Nagai, Hiroki, Maeno, Ken, Oguri, Tetsuya, Hirai, Toyohiro, Kim, Young Hak
Publicado 2017

CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer

por Ogimoto, Tatsuya, Ozasa, Hiroaki, Yoshida, Hironori, Nomizo, Takashi, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Yamazoe, Masatoshi, Ajimizu, Hitomi, Tsuji, Takahiro, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Morita, Satoshi, Hirai, Toyohiro
Publicado 2023

Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer

por Yamazoe, Masatoshi, Ozasa, Hiroaki, Tsuji, Takahiro, Funazo, Tomoko, Yoshida, Hiroshi, Hashimoto, Kentaro, Hosoya, Kazutaka, Ogimoto, Tatsuya, Ajimizu, Hitomi, Yoshida, Hironori, Itotani, Ryo, Sakamori, Yuichi, Kuninaga, Kiyomitsu, Aoki, Wataru, Hirai, Toyohiro
Publicado 2022

MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression

por Yasuda, Yuto, Ozasa, Hiroaki, Kim, Young Hak, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yamamoto Funazo, Tomoko, Nomizo, Takashi, Tsuji, Takahiro, Yoshida, Hironori, Sakamori, Yuichi, Nakajima, Naoki, Menju, Toshi, Yoshizawa, Akihiko, Date, Hiroshi, Hirai, Toyohiro
Publicado 2020

Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2021

Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer

por Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro
Publicado 2023

YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation

por Tsuji, Takahiro, Ozasa, Hiroaki, Aoki, Wataru, Aburaya, Shunsuke, Yamamoto Funazo, Tomoko, Furugaki, Koh, Yoshimura, Yasushi, Yamazoe, Masatoshi, Ajimizu, Hitomi, Yasuda, Yuto, Nomizo, Takashi, Yoshida, Hironori, Sakamori, Yuichi, Wake, Hiroaki, Ueda, Mitsuyoshi, Kim, Young Hak, Hirai, Toyohiro
Publicado 2020

Recurrence patterns and progression-free survival after chemoradiotherapy with or without consolidation durvalumab for stage III non-small cell lung cancer

por Kishi, Noriko, Matsuo, Yukinori, Shintani, Takashi, Ogura, Masakazu, Mitsuyoshi, Takamasa, Araki, Norio, Fujii, Kota, Okumura, Setsuko, Nakamatsu, Kiyoshi, Kishi, Takahiro, Atsuta, Tomoko, Sakamoto, Takashi, Ohtsu, Shuji, Katagiri, Tomohiro, Narabayashi, Masaru, Fujishiro, Satsuki, Iizuka, Yusuke, Ozasa, Hiroaki, Hirai, Toyohiro, Mizowaki, Takashi
Publicado 2022

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

por Katayama, Yuki, Yamada, Tadaaki, Tanimura, Keiko, Tokuda, Shinsaku, Morimoto, Kenji, Hirai, Soichi, Matsui, Yohei, Nakamura, Ryota, Ishida, Masaki, Kawachi, Hayato, Yoneda, Kazue, Hosoya, Kazutaka, Tsuji, Takahiro, Ozasa, Hiroaki, Yoshimura, Akihiro, Iwasaku, Masahiro, Kim, Young Hak, Horinaka, Mano, Sakai, Toshiyuki, Utsumi, Takahiro, Shiotsu, Shinsuke, Takeda, Takayuki, Katayama, Ryohei, Takayama, Koichi
Publicado 2023

A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

por Hazama, Shoichi, Nakamura, Yusuke, Tanaka, Hiroaki, Hirakawa, Kosei, Tahara, Ko, Shimizu, Ryoichi, Ozasa, Hiroaki, Etoh, Ryuichi, Sugiura, Fumiaki, Okuno, Kiyotaka, Furuya, Takumi, Nishimura, Taku, Sakata, Koichiro, Yoshimatsu, Kazuhiko, Takenouchi, Hiroko, Tsunedomi, Ryouichi, Inoue, Yuka, Kanekiyo, Shinsuke, Shindo, Yoshitaro, Suzuki, Nobuaki, Yoshino, Shigefumi, Shinozaki, Hirokazu, Kamiya, Akira, Furukawa, Hiroyuki, Yamanaka, Takeharu, Fujita, Tomonobu, Kawakami, Yutaka, Oka, Masaaki
Publicado 2014